Press

Klaria signs license agreement for Sumatriptan Alginate film in Europe with CNX Therapeutics

Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that the Company has signed a license agreement for Sumatriptan Alginate Film (the "Product"), a pharmaceutical product based on Klaria's patented alginate films for fast and reliable administration via the oral mucosa, which is approved in Germany, Spain and Italy for the treatment of migraine with or without aura, with CNX Therapeutics Limited (“CNX Therapeutics”). The agreement gives CNX Therapeutics the right to market and sell the Product in Europe and the UK under its own brand and product name, and the parties plan an initial launch in Germany, Spain and Italy in the second half of 2025 with further expansion in 2026. The agreement gives Klaria an up-front payment of EUR750,000, milestone payments of approx. EUR500,000 – 1,250,00 based on pricing per geographic market for the first 8 countries, as well as a double-digit royalty based on sales revenue. Furthermore, negotiable milestone payments are possible when expanding the market territory within the EEA.  In addition to the license agreement, Klaria has a long-term business relationship with AdhexPharma SAS, a leading CDMO located in France and Germany, as the parties’ production partner. Today, AdhexPharma has an annual production capacity of 200 million units, with plans to scale up to meet market demand for Sumatriptan Alginate Film.

Klaria Sumatriptan Alginate Film Receives Marketing Authorization

Klaria has been notified by the German Federal Institute for Drug and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) that the review process has concluded, and that marketing authorization for the treatment of migraine with and without aura is granted.

Klaria accelerates its business development efforts

With Klaria’s Sumatriptan Alginate Film product in approval process Klaria is now accelerating its business development efforts and has engaged Ernst & Young AB Corporate Finance (EY) to identify potential strategic partnerships for its assets. In line with this, several options are being considered that could lead to different potential outcomes, with the objective to maximize shareholder value.

Klaria’s board of directors announces that CEO Jesper Wiklund leaves the company

The board of Klaria Pharma Holding AB (publ) announces that Jesper Wiklund is leaving the CEO position to focus on other activities based in Germany. Fredrik Hübinette, the company’s chairman of the board, will assume the position as acting CEO with immediate effect during a transition period.

Bulletin from the annual general meeting in Klaria Pharma Holding AB (publ)

Klaria Pharma Holding AB (publ) issues notice to attend the annual general meeting

The Swedish Financial Supervisory Authority initiates investigation of Klaria Pharma’s handling and disclosing of inside information

Klaria receives 2,6 MSEK payment from Imbrium Therapeutics in the Epinephrine Alginate Film R&D Collaboration

Klaria Pharmaceuticals announced today that it has received additional funding from its partner Imbrium Therapeutics to fund additional research in the Epinephrine Alginate Film collaboration.  The partners are collaborating on the research and development of Epinephrine Alginate Film for the treatment of serious allergic reactions, so called Anaphylactic Shock. 

Outcome in Klaria’s rights issue

Klaria Pharma Holding AB: Klaria publishes prospectus relating to the rights issue and gives update regarding the level of undertaking of the rights issue

Klaria Pharma Holding AB (”Klaria” or the “Company") today announces that the prospectus relating to the Company's rights issue (the "Rights Issue") has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”, sw. Finansinspektionen) (the "Prospectus"). The Company also announces that the Rights Issue of up to SEK 74.0 M before issuing costs has been secured up to 80 per cent by an increased top guarantee undertaking.

Bulletin from the extraordinary general meeting in Klaria Pharma Holding AB (publ)

At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 November 2022, it was resolved to approve the board of directors’ resolution on issuance of shares with preferential rights for the shareholders (in accordance with the proposal presented in the notice to attend the meeting kept available at the company’s website www.klaria.com).